Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor,OncoImmunology

当前位置： X-MOL 学术 › Oncoimmunology › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
OncoImmunology ( IF 7.2 ) Pub Date : 2023-10-05 , DOI: 10.1080/2162402x.2023.2265703
Jingjing Zhao ₁ , Jiebin Dong ₁ , Changwen Deng ₂ , Qianjing Zhang ₁ , Shicheng Sun ₁ , Honggang Li ₁ , Yun Bai ₁ , Hongkui Deng _{1,

3}

Affiliation

Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated success in the treatment of hematological malignancies; however, its efficacy and applications in solid tumors remain limited. ...

中文翻译：